Related Experiment Video
Updated: Aug 7, 2026
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
Bronchodilators for bronchiolitis
1Mary Imogene Bassett Hospital, Research Institute, 1 Atwell Road, Cooperstown, NY 13326, USA. gadomski@usa.net
Insights
Bronchodilators offer minor, short-term symptom relief for infants with bronchiolitis, but their clinical benefit must be balanced against potential costs and side effects.
Area of Science:
- Pediatric Respiratory Medicine
- Evidence-Based Medicine
- Clinical Pharmacology
Background:
- Bronchiolitis is a common, highly infectious lower respiratory tract infection in infants.
- Bronchodilator use for bronchiolitis is prevalent in North America but not in the UK.
Purpose of the Study:
- To evaluate the efficacy of bronchodilators in improving clinical outcomes for infants diagnosed with acute bronchiolitis.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Searched multiple databases including CENTRAL, DARE, MEDLINE, and EMBASE.
- Included 22 RCTs involving 1428 infants, comparing bronchodilators (excluding epinephrine) with placebo.
Main Results:
- Bronchodilators showed a statistically significant but modest improvement in clinical scores (SMD -0.48).
- No significant improvement in oxygenation was observed (WMD -0.57).
- Subgroup analyses indicated greater effects in outpatients, but no reduction in hospital admission rates or duration.
Conclusions:
- Bronchodilators provide small, short-term clinical score improvements in infants with bronchiolitis.
- The limited benefits should be considered alongside the costs and potential adverse effects.
- Potential bias from including studies with recurrent wheezing populations was noted.
Background:
Bronchiolitis is an acute, highly infectious lower respiratory tract infection. Bronchodilators are commonly used in the management of bronchiolitis in North America but not in the United Kingdom.
Objectives:
The objective of this review was to assess the effects of bronchodilators on clinical outcomes in infants with acute bronchiolitis.
Search Strategy:
In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) and the Database of Abstracts of Reviews of Effects (DARE) (The Cochrane Library, Issue 1, 2006), MEDLINE (1966 to October 2005), EMBASE (2003 to September 2005) and the reference lists of articles. The files of one author (AG) were also reviewed.
Selection Criteria:
Randomized controlled trials (RCTs) comparing bronchodilators (other than epinephrine) with placebo in the treatment of bronchiolitis.
Data Collection And Analysis:
For this updated review, one author assessed trial quality and extracted data. Unpublished data were requested from study authors when necessary.
Main Results:
Twenty-two clinical trials with 1428 infants with bronchiolitis were included in this review. In eight trials, with 468 infants, there was no improvement in clinical score for 43% of those treated with bronchodilators compared to 57% of those treated with placebo (odds ratio (OR) for no improvement 0.45, 95% confidence interval (CI) 0.15 to 1.29). There was a statistically significant but clinically modest improvement in the overall average clinical score (standardized mean difference (SMD) -0.48, 95% CI -0.62 to -0.33). However there was no statistically significant improvement in oxygenation overall (weighted mean difference (WMD) -0.57, 95% CI -1.17 to 0.03). Subgroup analyses showed a slightly greater effect size in outpatient studies, where there were shorter follow up durations, than in inpatient studies for both oximetry (outpatients WMD -0.84, 95% CI -1.59 to -0.10 versus inpatients WMD -0.25, 95% CI -1.18 to 0.67) and average clinical score (outpatients SMD -0.68, 95% CI -0.87 to -0.49 versus inpatients SMD -0.23, 95% CI -0.44 to -0.01). Bronchodilator recipients showed no improvement in the rate of hospital admission after treatment as outpatients (18% versus 26%, OR 0.70, 95% CI 0.36 to 1.35) or duration of hospitalization for inpatients (WMD 0.02, 95% CI -0.32 to 0.36). The inclusion of studies that enrolled infants with recurrent wheezing may have biased the results in favor of bronchodilators.
Authors' Conclusions:
Bronchodilators produce small short-term improvements in clinical scores. This small benefit must be weighed against the costs and adverse effects of these agents.
Related Concept Videos
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:23Inhaled Medications
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...